Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Unknown 5Recruiting 5Completed 5Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 3OTHER_GOV 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Rectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 20Radiotherapy 16Paclitaxel 14Carboplatin 12pembrolizumab 11Drug Therapy 11tislelizumab 10Fluorouracil 8Neoadjuvant Therapy 7130-nm albumin-bound paclitaxel 7sintilimab 5Esophagectomy 5toripalimab 4Tegafur 4TP protocol 4Nivolumab 4Irinotecan 4Immunotherapy 4spartalizumab 3S 1 (combination) 3Oxaliplatin 3Leucovorin 3Itraconazole 3Docetaxel 3Albumin-Bound Paclitaxel 3nimotuzumab 2apatinib 2Taxes 2Radiotherapy, Intensity-Modulated 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Esophageal Squamous Cell Carcinoma × sintilimab × Clear all
NCT05357846 2026-04-30

PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

Sun Yat-sen University

Phase 3 Recruiting
422 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06709417 2024-11-29

A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)

Shanghai Chest Hospital

Phase 2 Recruiting
52 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05495152 2024-10-02

Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma

Henan Cancer Hospital

Phase 3 Recruiting
219 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06463834 2024-06-18

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06190639 2024-01-05

A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC

Zhejiang Cancer Hospital

Phase 2 Recruiting
31 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡